Protalix BioTherapeutics Inc. (DE) (PLX)
PLX trades on NYSE in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1006281/000110465926029858/0001104659-26-029858-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | PLX on NYSE |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | Israel |
| IPO year | Not reported by the screener |
| SEC CIK | 0001006281 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $52.7M |
| Net income | -$6.6M |
| Operating income | -$5.5M |
| Net margin | -12.5% |
| Operating margin | -10.4% |
| Revenue growth | -1.2% |
| Cash | $14.7M |
| Total assets | $82.3M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 4.8× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-10 |
| Cash and burn | $22.0M cash; operating cash flow $4.4M a quarter. | Report 2026-09-30 |
| Shares outstanding | 84,318,923 (2026-11-01); 80,421,181 a year earlier; 72,952,124 three years earlier. | Cover page 2026-11-01 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Kesselman & Kesselman C.P.A.s, Tel-Aviv, Israel | PCAOB Form AP 2026-03-30 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $101K, sold $314 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $21.9M | $4.0M | $3.9M | $22.0M | No debt tags | $84.7M | 10-Q 2026-11-10 |
| Q2 2026 2026-06-30 | $19.9M | $3.8M | -$10.4M | $27.4M | No debt tags | $80.6M | 10-Q 2026-08-12 |
| Q1 2026 2026-03-31 | $33.8M | $18.3M | $22.0M | $41.0M | No debt tags | $76.4M | 10-Q 2026-05-13 |
| Q4 2025 2025-12-31 | $9.1M | -$5.5M | $2.0M | $14.7M | No debt tags | $52.7M | 10-K 2026-03-18 |
| Q3 2025 2025-09-30 | $17.9M | $2.4M | -$3.7M | $13.6M | No debt tags | $61.8M | 10-Q 2026-11-10 |
| Q2 2025 2025-06-30 | $15.7M | $164K | -$5.2M | $17.9M | No debt tags | $61.9M | 10-Q 2026-08-12 |
| Q1 2025 2025-03-31 | $10.1M | -$3.6M | -$5.1M | $19.5M | No debt tags | $59.8M | 10-Q 2026-05-13 |
| Q4 2024 2024-12-31 | $18.2M | $6.5M | $4.0M | $19.8M | $0 | $53.4M | 10-K 2026-03-18 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2025-08-22 |
| Latest annual report | 10-K | 2026-03-18 |
| Latest quarterly / interim | 10-Q | 2026-11-10 |
| Latest current report | 8-K | 2026-11-10 |
| Latest proxy | DEF 14A | 2026-04-30 |
Source: SEC EDGAR submissions feed, 974 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +20.1% |
| 1 month | +10.9% |
| 3 months | +29.2% |
| Year to date | +69.4% |
| 1 year | +58.0% |
| From 52-week high | -3.2% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| OCGN | Ocugen Inc. | $0.7730 | -6.62% | $262.3M |
| LXEO | Lexeo Therapeutics Inc. | $3.23 | +12.54% | $265.0M |
| SABS | SAB Biotherapeutics Inc. | $3.00 | +1.35% | $270.3M |
| CABA | Cabaletta Bio Inc. | $1.11 | -13.28% | $239.4M |
| DTIL | Precision BioSciences Inc. | $7.28 | -3.77% | $277.6M |
| ALLO | Allogene Therapeutics Inc. | $0.8070 | -3.78% | $279.6M |
| AGEN | Agenus Inc. | $6.29 | -6.54% | $284.6M |
| EDIT | Editas Medicine Inc. | $1.87 | -13.82% | $288.6M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier